Waystar Holding Corp. (WAY) Stock Price & How to Invest

Last updated November 2026

Short answer

WAY is Waystar Holding, a cloud healthcare-payments (revenue cycle management) software company that went public in 2024 and now runs profitably at scale. Investing in it is a bet on hospitals and clinics standardizing their billing and collections on a single platform, with AI-driven claims and denials tooling as the growth wedge. In September 2026 Reuters reported that Waystar had hired Evercore to explore options including a possible sale; no deal had been announced as of November 20, 2026, when the shares closed near $26.72, down about 15% year to date and 23% over the past year, after a third quarter that beat estimates but came with a slightly light revenue outlook.

WAY stock price

As of 2026-11-20, Waystar Holding Corp. (WAY) last closed at $26.52, down 25.8% over the past year. Over the past 52 weeks it has traded between $17.31 and $37.04.

WAY last close
$26.52
1 day
-2.10%
1 month
-8.04%
1 year
-25.80%
52-week range
$17.31 to $37.04
Last close
2026-11-20

Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Waystar Holding Corp.'s investor relations page. Walnut is informational, not investment advice.

WAY key stats

At $26.52 on November 20, 2026, Waystar Holding Corp. (WAY) has a market cap of $5.1B and a P/E of 38.4 on trailing earnings (14.1 on forward earnings).

Market cap
$5.1B
P/E (trailing)
38.4
P/E (forward)
14.1
EPS (trailing 12 months)
$0.69
Price to book
1.3
Beta
0.11

Market cap, P/E and yield are measured at the $26.52 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with Waystar Holding Corp. (WAY)?

The last two weeks for Waystar Holding Corp., as of November 22, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.

  • WAY closed at $26.52 on November 20, 2026, down 5.3% over the past five trading days (from $27.99).

Waystar Holding Corp. filed no current, quarterly or annual report with the SEC in the last two weeks.

Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

Waystar Holding Corp. (WAY) latest quarter

Waystar reported revenue of $326 million for Q3 2026, up 21% from a year earlier (Waystar, Nov 2, 2026).

Revenue
$326 million
up 21% from a year earlier
Diluted EPS (GAAP)
$0.16
down 6% from a year earlier
Subscription revenue
$181 million
up 34% from a year earlier

Source: Waystar Q3 2026 results, Nov 2, 2026. Full earnings breakdown

What does Waystar Holding Corp. (WAY) do?

Waystar Holding (Nasdaq: WAY) sells cloud-based software that healthcare providers use to get paid: financial clearance and eligibility, claims and payer-payment management, denials prevention and recovery, patient payments, and analytics. Its platform sits between roughly a million providers and the payers that reimburse them, processing billions of transactions a year, and the company leans heavily on automation and AI to reduce the manual work in medical billing. Provider-side solutions make up the large majority of revenue and carry high margins, with patient-payment tools rounding out the mix.

The investment picture is one of a scaled, sticky software business that turned the corner on GAAP profitability after its 2024 IPO. Revenue grew about 22% year over year in Q1 2026 (roughly 11% organic, the rest from the Iodine Software acquisition), about 18% in Q2 2026 to roughly $320 million, and about 21% in Q3 2026 to roughly $326 million, ahead of the $323 million consensus. Third-quarter adjusted EPS of $0.44 beat the $0.41 estimate, adjusted EBITDA was about $139 million (a 43% margin), and subscription revenue rose 34%. Net revenue retention slipped to about 108% from roughly 111% earlier in the year. The reaction was negative anyway: full-year revenue guidance of $1.277 billion to $1.287 billion came in below the roughly $1.29 billion consensus, and the shares fell about 7% after hours on November 2. Trailing revenue is now about $1.26 billion and trailing net income about $135 million.

The debate is less about whether the business works and more about valuation: at about 39 times trailing GAAP earnings (but around 14 times 2027 adjusted EPS estimates) and a ~$5.1 billion market cap, roughly 4.1 times trailing revenue, the stock already embeds expectations for sustained growth, successful acquisition integration, and further margin gains. The stock fell hard in the first half of 2026, hitting a 52-week low near $17.26, then rebounded after the strong second quarter and after Reuters reported on September 15 that Waystar was exploring options, including a potential sale, with Evercore advising. The talks were described as early stage, and Barclays downgraded the stock to equal weight the next day. Since the third-quarter report, Truist and Deutsche Bank have raised their price targets, and in November West Virginia University Health System picked Waystar's platform for its end-to-end revenue cycle operations.

What's driving Waystar Holding Corp. (WAY)?

1. AI-driven revenue cycle automation

Waystar has pushed AI features across claims, denials, and prior authorization, and management said AI-powered capabilities drove roughly 40% of new bookings in Q1 2026; on the third-quarter call it again pointed to a surge in AI bookings. Because medical billing is labor-intensive and error-prone, automation that lifts clean-claim rates and recovers denials is a concrete efficiency pitch to providers. This is the clearest lever the company points to for both new-logo wins and expansion within existing accounts, and the November 2026 WVU Medicine selection is a recent example of a large health system adopting the platform end to end.

2. Land-and-expand with high retention

Net revenue retention of about 108% in Q3 2026 (down from roughly 111% earlier in the year) means existing customers still spend more each year as they adopt additional modules across the platform. Provider revenue grew about 28% in the third quarter against about 5% for patient payments, and clients generating more than $100,000 of trailing revenue rose 14% to 1,488, so cross-selling more of the suite into an already-large installed base remains the main growth engine. High switching costs in mission-critical billing systems reinforce the stickiness.

3. Iodine acquisition and platform breadth

The Iodine Software acquisition extended Waystar into mid-cycle and clinical-integrity capabilities, and management has said the integration is running ahead of schedule. Bolting complementary capabilities onto one platform lets Waystar sell a broader footprint to the same providers. Continued M&A and cross-sell of acquired capabilities are central to the growth story.

4. Structural demand for billing efficiency

US healthcare billing is famously complex, and providers face persistent margin pressure that makes faster, cleaner collections valuable. The addressable market for RCM software and transactions is often estimated in the $15-20 billion range annually. As a scaled independent platform, Waystar is positioned to consolidate share as providers move off fragmented legacy tools.

5. A possible sale process

On September 15, 2026 Reuters, citing people familiar with the matter, reported that Waystar was exploring strategic options including a sale and had hired Evercore as adviser; the shares rose more than 8% that day. The process was described as early stage, no buyer or price was reported, and the company had not announced any agreement as of November 20, 2026. Until there is a signed deal, the stock still trades on its operating results, as the 7% drop on the November guidance showed, but takeover speculation sits in the price and could reverse if no transaction emerges.

What are the risks to Waystar Holding Corp. (WAY)?

Concentration and competition are real: Optum (UnitedHealth) can bundle RCM with payer services and undercut on price, while R1 RCM, Availity, and Experian Health all compete for overlapping share. Valuation is the sharpest risk, as a trailing P/E near 39 leaves little room for a growth or margin stumble, and the November 2026 reaction to a full-year revenue range about 1% below consensus showed how little slack the market gives. The stock remains well below its 52-week high of about $37.51. Part of its rebound from the spring low followed reports of a possible sale, so a process that ends without a deal could take some of it back. Growth is partly acquisition-fueled and net revenue retention eased to about 108%, so integration missteps or slowing organic growth would matter, and the business carries meaningful debt from its buyout and IPO history (about $1.48 billion against roughly $279 million of cash as of September 2026). Regulatory change in healthcare reimbursement, payer-side pricing pressure, and cybersecurity exposure (a systemic concern for healthcare-payments infrastructure after the 2024 Change Healthcare breach) round out the risk set.

What is the Waystar Holding Corp. (WAY) forecast?

22 analysts publish price targets on WAY, averaging $34.82 as of November 2026, or +31.3% against the $26.52 share price on November 20, 2026. The published targets run from $28.00 to $44.00, a moderate spread, and the ratings split 21 buy, 2 hold, 0 sell. Over the last six months there have been 7 raises and 2 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full WAY forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

Is WAY a buy or a sell?

We give no verdict on Waystar Holding Corp.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. AI-driven revenue cycle automation. Waystar has pushed AI features across claims, denials, and prior authorization, and management said AI-powered capabilities drove roughly 40% of new bookings in Q1 2026; on the third-quarter call it again pointed to a surge in AI bookings. The most optimistic published target, $44.00, assumes this works close to its best case.

The case against. Concentration and competition are real: Optum (UnitedHealth) can bundle RCM with payer services and undercut on price, while R1 RCM, Availity, and Experian Health all compete for overlapping share. The most pessimistic target, $28.00, is roughly what WAY is worth if this bites instead.

Read the full bull and bear case on WAY, including what would have to change to break either one. Walnut is not an investment adviser.

Has Waystar Holding Corp. (WAY) split its stock?

No. Waystar Holding Corp. (WAY) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

How is Waystar Holding Corp. (WAY) valued?

Market cap, P/E and dividend yield at today's price are in the WAY key stats above. The business figures below come from Waystar Holding Corp.'s reported results as of November 2026 and change when it next reports.

  • Revenue (TTM): ~$1.26B (+21% YoY in Q3 2026)
  • Q3 2026 adj. EPS: $0.44 vs $0.41 est.
  • Net income (TTM): ~$135M (~11% net margin)
  • Q3 2026 adj. EBITDA: ~$139M (~43% margin)
  • 2026 guidance (November): Revenue $1.277B-$1.287B; adj. EPS $1.63-$1.71

As of November 2026: Waystar closed at about $26.72 on November 20, 2026, up about 10% over three months and well above its 52-week low near $17.26, but down roughly 23% from a year earlier. Q3 2026 revenue rose ~21% to ~$326 million and adjusted EPS of $0.44 beat the $0.41 estimate, but the trimmed full-year revenue range sent the stock lower. The trailing GAAP P/E near 39 and a market cap of about 4.1 times trailing revenue reflect expectations for continued double-digit growth, while the forward multiple of about 14 times 2027 adjusted EPS looks lower because adjusted figures exclude amortization and stock compensation; the 22 analysts covering the stock carry a mean target near $34.82, and the price also includes some takeover speculation.

Who competes with Waystar Holding Corp. (WAY)?

Payer-integrated giants

Optum (UnitedHealth) is the heavyweight, using a $220B+ ecosystem to bundle RCM with payer services and compete on integrated payer-provider workflows. Its scale and pricing leverage make it the most structurally threatening competitor to independent platforms like Waystar.

Full-service RCM outsourcers

R1 RCM competes for providers that prefer to outsource the entire revenue cycle rather than license software. Waystar instead sells technology that hospitals can adopt without full outsourcing, so the two overlap most where providers weigh build-and-license against hand-it-off models.

Clearinghouse and eligibility peers

Availity and Experian Health compete on clearinghouse connectivity, eligibility, and front-end transaction volume, the same lanes where Waystar is strong. These are the closest like-for-like rivals for Waystar's core provider-side software.

What stocks are similar to Waystar Holding Corp. (WAY)?

Other names that sit close to WAY: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.

How to invest in Waystar Holding Corp. (WAY)

There are three common ways to get WAY exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so WAY sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where WAY fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

The bottom line on Waystar Holding Corp. (WAY)

Waystar is a profitable, fast-growing healthcare-payments software business whose valuation already prices in durable double-digit growth and continued margin expansion; its latest quarter beat on revenue and EPS, and the share price still carries speculation about a possible sale that has not been confirmed.

More on Waystar Holding Corp. (WAY)

Whether WAY is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is WAY a buy or a sell?, and where the stock could go from here in the WAY stock forecast.

For income investors, whether WAY pays a dividend and how the payout looks is covered in does WAY pay a dividend? And to weigh WAY against a peer, read the full side-by-side comparisons: WAY vs UNH and WAY vs EXPGY.

Wondering how WAY fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Waystar Holding Corp.

Ask Walnut's AI anything about WAY and see how it fits what you own.

FAQ

What does Waystar (WAY) do?

+

Waystar provides cloud-based software that healthcare providers use to get paid. Its platform handles eligibility and financial clearance, claims and payer-payment management, denials prevention and recovery, patient payments, and analytics, processing billions of transactions a year across roughly a million providers.

Is Waystar profitable?

+

Yes. After its 2024 IPO, Waystar turned GAAP-profitable, reporting roughly $135 million in trailing-twelve-month net income as of September 2026 and adjusted EBITDA margins in the low-40s percent. Net income was about $43 million in Q1 2026, $41 million in Q2 and $31 million in Q3, when adjusted EBITDA reached about $139 million.

How fast is Waystar growing?

+

Revenue grew about 22% year over year in Q1 2026 to roughly $314 million, of which about 11% was organic and the rest came from the Iodine Software acquisition, about 18% in Q2 2026 to roughly $320 million, and about 21% in Q3 2026 to roughly $326 million. Full-year 2026 revenue guidance updated in November is $1.277 billion to $1.287 billion, slightly below the roughly $1.29 billion analysts had expected, and consensus for 2027 sits near $1.42 billion.

Who are Waystar's main competitors?

+

Chief competitors include Optum (UnitedHealth), which bundles RCM with payer services, and R1 RCM in full-service outsourcing. On clearinghouse and eligibility technology, Waystar competes most directly with Availity and Experian Health.

What is the bull case for WAY?

+

The bull case rests on a sticky platform with net revenue retention near 108%, AI features driving a large share of new bookings, cross-selling more modules into a large installed base (provider revenue grew 28% in Q3 2026), and continued margin expansion, all inside a $15-20 billion addressable market.

What are the biggest risks for WAY?

+

Key risks are competition from a scaled, price-bundling Optum, a trailing P/E near 39 that leaves little room for error, reliance on acquisitions for part of its growth, meaningful debt, healthcare reimbursement regulation, cybersecurity exposure inherent to healthcare-payments infrastructure, and the chance that a reported sale process ends without a deal.

Why did WAY stock trade below its highs in 2026?

+

Despite strong results, the stock fell to a 52-week low near $17.26 in the first half of 2026 as the market repriced a richly valued software name, weighing continued growth and margin gains against a high multiple and competitive pressure. It rebounded after a second-quarter beat and reports of a possible sale, then slipped again after the November 2026 guidance, closing near $26.72 on November 20, down about 15% year to date and well below its $37.51 52-week high.

How does Waystar make money?

+

Waystar earns subscription and transaction-based revenue from software that providers use for billing and collections. High-margin provider solutions make up the large majority of revenue, with patient-payment tools contributing the remainder.

Is Waystar being sold?

+

Not as of November 20, 2026. Reuters reported on September 15, 2026 that Waystar was exploring options including a potential sale and had hired Evercore as an adviser, and the stock rose more than 8% that day. The discussions were described as early stage, no buyer or price was reported, and the company has not announced any agreement. Walnut is not an investment adviser, and a reported process can end without a transaction.

How did Waystar do in its latest quarter?

+

In the third quarter of 2026, reported November 2, Waystar posted revenue of about $326 million, up roughly 21% year over year and ahead of the $323 million consensus, net income of about $31 million, and adjusted EPS of $0.44 against a $0.41 estimate. Subscription revenue rose 34% and adjusted EBITDA margin was about 43%. It has beaten EPS estimates in three of the last four quarters, but the full-year revenue range of $1.277 billion to $1.287 billion fell short of consensus and the shares dropped about 7% after hours.

How has WAY stock performed in 2026?

+

As of November 20, 2026, Waystar closed at about $26.72, down roughly 15% year to date and 23% over the past year, though up about 10% over three months from its spring lows. Its 52-week range is about $17.26 to $37.51. After the third-quarter report Truist raised its target to $35 and Deutsche Bank to $42, and the analyst mean is near $34.82. Past performance does not predict future returns, and Walnut is not an investment adviser.

Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Waystar Holding Corp.'s investor relations page or your broker before making investment decisions.